Shubhshree Bio. (SHUBHSHREE)

Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• High promoter holding of 73.58% aligns management interests with minority shareholders.
• Latest quarter shows positive net profit of ₹4 Cr on sales of ₹96 Cr, implying a small positive net margin of about 4.2%.
• Small market cap of ₹164 Cr gives niche investors room if genuine growth emerges.
• Current price of ₹320 is below the 52-week high of ₹380, so the stock is not at a recent euphoric peak.

Concerns

• Piotroski F-Score of 2/9 signals weak financial health and poor operating efficiency.
• Sales growth and profit growth are both 0.00%, making the 20.22 P/E look expensive without an expansion story.
• ROCE reported as 0.00% suggests capital employed is not generating a measurable operating return.
• No dividend yield, no book value, and no ROE data make it impossible to estimate a margin of safety.

AI Analysis

At ₹320, Shubhshree Bio carries a market cap of only ₹164 Cr and a price-to-earnings multiple of 20.22. I was taught by Graham to begin with hard facts: book value, return on equity, debt levels. Here, those are missing. ROCE is shown as 0.00%, and the Piotroski F-Score is just 2 out of 9. That is a serious warning. It says the company scores badly on profitability, leverage, and operating efficiency, which makes me doubt the quality of its earnings. Sales growth and profit growth are both 0.00%. There is no growth engine to justify a 20 times earnings price. The latest quarter reports sales of ₹96 Cr and net profit of ₹4 Cr, so the company is earning a small positive margin of about 4.2%. But that is hardly an impressive return, and with no dividend, I am not being paid to wait. On the positive side, promoters hold 73.58%, so their interests are aligned with mine. Yet high ownership alone does not create a moat. The 52-week range of ₹274 to ₹380 shows an unsettled market, and the current price of ₹320 gives me no obvious cushion. I cannot compute book value or ROE, so I cannot apply my usual margin-of-safety test. In this situation, the rational course is to stay away until better data and a clearer path to growth appear.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer